Rabpharma Successfully Closes Oversubscribed Series A++ Funding Round to Accelerate R&D Progress
Early-Stage Osteonecrosis Phase II Clinical Trial Patient Recruitment
The Fifth Meeting of the First Session of the Board of Directors & 2024 Annual Shareholders' Meeting of Rabpharma Successfully Concluded
Phase II Clinical Trial of RAB001 Officially Launched at Beijing Jishuitan Hospital and The Third Affiliated Hospital of Guangzhou University of Chinese Medicine!
Phase II Clinical Trial of RAB001 Officially Launched at Peking University Third Hospital!
